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  33 
Summary 34 
Ureaplasma spp. are a genus of bacteria for which two human associated species exist; Ureaplasma 35 
urealyticum and Ureaplasma parvum.  Their definition as a pathogen in the context of non-gonococcal 36 
urethritis and infertility among males remains highly controversial, largely due to historically high 37 
isolation rates of these bacteria from the urethra of seemingly healthy men.  This review summarises 38 
the emerging evidence suggesting a true pathogenic role of these bacteria under specific conditions, 39 
which we term as risk factors. We examine the historical, clinical and experimental studies which 40 
support a causal role for Ureaplasma spp in the development of NGU as well as some of the proposed 41 
mechanisms behind the association of Ureaplasma spp. and the development of infertility.  Finally, 42 
we discuss the potential for developing a case-by-case risk-based approach towards the management 43 
of men who present with seemingly idiopathic NGU, but are positive for Ureaplasma spp. 44 
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  47 
Introduction 48 
Non-gonococcal urethritis (NGU) is a leading sexually acquired condition among men. It is defined by 49 
inflammation of the urethra in the absence of Neisseria gonorrhoeae and includes signs and symptoms 50 
such as penile discharge, dysuria as well as irritation inside and around the urethra. Chlamydia 51 
trachomatis has long been regarded as the predominant infectious agent among patients suffering 52 
from NGU, with 20 – 50% of individuals being positive for the pathogen, whereas more recently, 53 
Mycoplasma genitalium has achieved recognition as a pathogen and may be isolated from 10-30% of 54 
NGU patients (1). Although C. trachomatis and M. genitalium account for many cases of NGU, of 55 
concern is the high prevalence of up to 45% of idiopathic NGU cases, in which classic pathogens are 56 
not identified (2).  57 
A leading candidate to fill the void presented by this idiopathic condition among NGU patients are 58 
bacteria from the genus Ureaplasma. The first documented isolation of these bacteria were from male 59 
patients experiencing NGU (3).   Many reports have followed up this observation with a view to gather 60 
evidence to support the idea of Ureaplasma spp. being an aetiological agent of NGU, but the 61 
combination of inconsistencies in reporting, study design and high prevalence of between 5 – 15% 62 
among healthy males aged 16 – 44 years has prevented the acknowledgment of these organisms as 63 
true pathogens in the context of genito-urinary medicine (GUM) (4). For these reasons, the idea of 64 
Ureaplasma spp. as GUM pathogen remains controversial among GUM practitioners. Additionally, the 65 
potential role of Ureaplasma spp. as agents with a causal role in male infertility has been debated. 66 
Many of the recognised GUM pathogens, such as N. gonorrhoeae and C. trachomatis, have been 67 
implicated in complications such as male infertility, but more work is required to gain a clear 68 
understanding on the implications associated with a failure to clear Ureaplasma spp. from the urethra 69 
(5). 70 
In this review we present an update from the current literature to discuss the potential of Ureaplasma 71 
spp. as a risk factor for male genital tract infections with specific reference to NGU and infertility.  In 72 
the context of NGU we present the arguments for and against a role for these bacteria in disease 73 
development with a focus on some of the unique risk factors which have been overlooked historically. 74 
Increasing interest has focused towards Ureaplasma spp. and their potential role in the development 75 
of male infertility. We discuss the clinical evidence as well as the proposed mechanisms which have 76 
been neglected when taking into account markers for infertility. Finally, the potential therapeutic 77 
considerations are evaluated and we discuss the potential for risk-based screening approaches as an 78 
effective means to manage patients with seemingly idiopathic NGU in the face of growing concerns 79 
over antimicrobial resistance among GUM pathogens. 80 
Background biology of Ureaplasma spp. 81 
Ureaplasma spp. are recognised as some of the smallest self-replicating, free-living microorganisms.  82 
They are a unique genera of bacteria due to their essential requirement for urea in the synthesis of 83 
ATP, with further defining characteristics shared with the closely related mycoplasmas, including a low 84 
G+C genomic content, lack of a peptidoglycan containing cell wall and requiring cholesterol for growth 85 
(6, 7). 86 
Ureaplasmas were first isolated from male NGU patients in 1954 and due to the tiny colony size upon 87 
agar plates, these bacteria were originally referred to as ‘T-Strain’ or ‘tiny mycoplasmas’ (3).  Following 88 
the establishment of the essential requirement for urea, the genus Ureaplasma was adopted (8).  A 89 
single species of human-associated Ureaplasma were initially recognised, Ureaplasma urealyticum, 90 
which was further sub-divided into two biovars.  The nomenclature of U. urealyticum for describing 91 
all human-associated isolates was embedded until the work by Roberston et al. in 2002, which made 92 
substantial contribution to redefining these bacteria into two antigenically distinct human associated 93 
species (9).  These were defined as U. urealyticum and Ureaplasma parvum.  The two species are 94 
divided into fourteen serovars with serovars 1, 3, 6 and 14 being assigned to U. parvum with the 95 
remaining serovars 2, 4-5 and 7-13 being defined as U. urealyticum. 96 
Numerous clinical manifestations have been associated with Ureaplasma spp. Among the most 97 
notable is the role of Ureaplasma spp. in adverse pregnancy outcomes such as chorioamnionitis and  98 
preterm premature rupture of membranes leading to preterm birth (10, 11).  The subsequent 99 
colonisation of Ureaplasma spp. within the lungs of premature neonates has been associated with a 100 
7.9-fold increased risk of bronchopulmonary dysplasia, 3.3-fold increased risk of intraventricular 101 
hemorrhage and a 2.5-fold increased risk of necrotising enterocolitis (12).  In adults, attention has 102 
been drawn towards the development of an atypical hyperammonaemia in which lung transplant 103 
patients, and potentially kidney transplant patients, have increased serum ammonia levels as a result 104 
of systemic Ureaplasma spp. infection (13-15).  If left untreated with antibiotics, such increased serum 105 
ammonia levels can lead to delirium, cerebral oedema and eventual fatality. 106 
Historically the link between Ureaplasma spp. and development of NGU, as well as infertility, 107 
prostatitis and epididymitis among men, has been inconsistent.   The reason for this, however, is 108 
certainly not from a lack of studies examining potential associations between Ureaplasma spp. and 109 
NGU (2, 16-21). Rather, the lack of conclusive evidence may reflect the complex interaction between 110 
host and pathogen, as discussed later, combined with the high prevalence of Ureaplasma spp. among 111 
control groups which suggests they are innocent bystanders present at time of screening.  Although 112 
Ureaplasma spp. were isolated approximately 30 years prior to Mycoplasma genitalium, the latter has 113 
risen to prominent pathogen status more rapidly, and new guidelines for its management are now in 114 
place in the UK (3, 22, 23) .   115 
The proinflammatory potential of Ureaplasma spp. 116 
Human volunteer experiments with Ureaplasma spp. infection of the urethra 117 
To demonstrate the pathogenicity of Ureaplasma spp., several investigators have undertaken human 118 
participant experiments (24, 25).  The first such experiment by Jänsch in 1972 identified a 119 
polymorphonuclear (PMN) response following inoculation with an unknown and poorly defined 120 
Ureaplasma spp. (24).  Although the experiment was poorly designed and controlled for, this gave an 121 
initial insight into the inflammatory nature of a human infection with Ureaplasma spp.  A second more 122 
defined experiment was conducted with two human participants.  The first participant received an 123 
intra-urethral inoculation of a clinically relevant titre of a low passage clinical isolate of U. urealyticum 124 
serovar 5 isolated from a patient experiencing NGU in which no other organisms were present (25).  125 
The participant subsequently developed symptoms of dysuria and signs of urethritis in the form of a 126 
PMN response.  The serum recovered from the volunteer demonstrated sero-conversion with high 127 
titres of specific antibodies.  Upon administration of tetracycline, both signs and symptoms resolved.  128 
The second participant received an alternative isolate of U. urealyticum serovar 5 isolated from a 129 
second patient presenting with NGU.  Again, signs and symptoms ensued, but upon administration of 130 
tetracycline signs, such as urinary threads, persisted in the absence of viable cultures.  Seminal 131 
samples collected post-antibiotic treatment indicated that the U. urealyticum had disseminated 132 
suggesting potential involvement of the prostate and highlighting the potential adverse sequelae 133 
associated with exposure to Ureaplasma spp.  Although such experiments are ethically questionable 134 
by today’s standards, these studies provided initial evidence that exposure of the male urethra to 135 
clinically relevant titres of U. urealyticum has the capacity to elicit a PMN immune response in the 136 
presence of symptoms which reflects those seen among NGU patients. It should be noted, however, 137 
that what a ‘clinically relevant titre’ of U. urealyticum is was not defined in this study and is a notable 138 
limitation for interpretation of these data. 139 
Animal models of Ureaplasma spp.-induced urethritis 140 
Due to substantial ethical implications of human volunteer studies, investigators turned to model 141 
urethral infection caused by Ureaplasma spp. utilizing animal models.  Like that of Neisseria 142 
gonorrhoeae, Ureaplasma spp. are host-specific, resulting in an early reliance upon chimpanzee 143 
models due to the close ancestry with humans. Initial experiments with intra-urethral inoculation saw 144 
rapid multiplication of the bacteria within the urethra, but in the absence of a PMN response (26). A 145 
possible explanation for this lack of immune response was suggested to be a loss of virulence from in 146 
vitro passage.  To examine this hypothesis a second study was conducted with a larger number of 147 
chimpanzees (27).  The inoculum for this study consisted of Ureaplasma spp. from men with NGU 148 
resuspended in a transport media which was directly inoculated into the chimpanzees via intra-149 
urethral inoculation.  Unlike the first study, a substantial PMN response was noted in conjunction with 150 
an increase in Ureaplasma spp. titre.  For reasons which are unknown, the species of Ureaplasma 151 
which was inoculated during this study was not determined.    152 
Due to the lack of availability of chimpanzee models, investigators have moved to murine models to 153 
investigate colonisation of the genital tract (28-30).  Although many of these models have relied upon 154 
female mice and vaginal colonisation, due to the physiology of the male mouse urethra, an 155 
inflammatory response as characterised by increased TNF-α and PMN recruitment have been 156 
described.  A key confounding variable has been the essential requirement to pre-treat the mice with 157 
estradiol to allow for colonisation to establish.  This requirement for estradiol is likely due to 158 
suppression of the innate immune system, but the presence of estradiol binding proteins as seen in 159 
other pathogens are yet to be ruled out (31, 32). 160 
In vitro cell line models of Ureaplasma spp.-induced inflammation 161 
The difficulty in assessing Ureaplasma spp. infection of the urethra has resulted in a reductionist 162 
approach utilising specific cell lines in isolation in vitro to look at cytokine responses.  Some studies 163 
have focused on immune cells such as THP-1 monocytes, phorbol myristate acetate (PMA) 164 
differentiated macrophages and primary human macrophages derived from lung fluid which were 165 
then stimulated with U. urealyticum serovar 8 (33).  In all cell types examined, stimulation with U. 166 
urealyticum resulted in a dose-dependent increase in levels of IL-6 and TNF-α at both the mRNA and 167 
protein level.  However, it should be noted that studies examining cytokine expression in relation to 168 
stimulation by Ureaplasma spp. tend to examine a single bacterial isolate and therefore do not give a 169 
true representation of the diversity of stimulating properties of Ureaplasma spp.  It has been 170 
suggested that the predominant antigen found on the surface of Ureaplasma spp., known as the 171 
multiple banded antigen (MBA), may account for differences in inflammatory response (34).  Sweeny 172 
et al., noted that the size and number of MBA repeats had an effect upon the levels of IL-8 which is a 173 
primary chemoattractant of PMNs such as neutrophils (34).  Although many of these studies were 174 
generalised for the immunogenic properties of Ureaplasma spp. they provide evidence for the 175 
inflammatory potential for these bacteria.  An obvious limitation of these studies is the lack of 176 
consideration towards the complexities of a full biological system such as adaptive immune response, 177 
the presence of other microorganisms which may permit infection as well as the response to chronic 178 
exposure over time.   179 
Risk factors linked with the development of Ureaplasma spp. 180 
associated NGU 181 
Ureaplasma spp. can be detected in genital samples from men with NGU as well as healthy controls, 182 
which has fuelled much of the controversy surrounding the role of Ureaplasma spp. in NGU (Table 1).  183 
Much of this historic evidence may now be questioned due to developments in the reclassification of 184 
Ureaplasma spp., better techniques for species differentiation, fully quantitative reporting of sample 185 
titre, as well as a better understanding of patient sexual histories. A proposed overview of the natural 186 
history of Ureaplasma spp. taking into account these risk factors is presented in Figure 1. 187 
 188 
Risk factor 1: The species of Ureaplasma present within the urethra. 189 
Until 2002 human ureaplasmas were recognised as a single species subdivided into two biovars.  The 190 
result of phenotypic and genotypic analysis later saw the official recognition of two-independent 191 
species, U. parvum and U. urealyticum (9).  This absence of species differentiation meant that studies 192 
prior to 2002 solely reported results as U. urealyticum and therefore may have over represented this 193 
species among clinical samples from both cases as well as control groups.   The legacy of the original 194 
nomenclature is still evident today, with publications still referring to U. urealyticum or just 195 
Ureaplasma spp., and may be partially attributed to the use of culture-based rapid diagnostic kits 196 
which are commercially available (35). Over time, studies have begun to differentiate the Ureaplasma 197 
spp. found into the respective species, with some studies identifying the presence of U. urealyticum 198 
more often among NGU patients than controls, whereas U. parvum represented the inverse of this 199 
(17, 21, 36-39).    In many of these studies, patient numbers in both NGU and control groups were 200 
seen as low and therefore lacked the power to confidently associate U. urealyticum with NGU.  For 201 
this reason, Zhang et al. performed a meta-analysis which included seven eligible case-control studies 202 
encompassing 1507 NGU patients and 1223 controls from four separate continents (40).  The findings 203 
identified that U. urealyticum was more prevalent among NGU patients than controls and U. parvum 204 
was significantly more associated with the control group than those with NGU.  This analysis gave 205 
significant weighting towards the idea that U. urealyticum is the most commonly associated species 206 
of Ureaplasma among NGU patients and presents as a substantial risk factor for development of 207 
disease, although some studies have found the inverse result (41).   208 
Due to the link between species and disease, it is essential that future studies differentiate 209 
Ureaplasma spp. from clinical samples using molecular methods to the species level to aid in 210 
epidemiological studies which will either support or refute the role of these bacteria in the 211 
development of NGU. One of the limiting factors inhibiting this is the use of culture-based rapid 212 
diagnostic tests available commercially, which are able to yield semi-quantitative data with regards to 213 
titres with in a sample, as well as an indication of antibiotic susceptibility, but they are of limited 214 
diagnostic use in the instance of NGU due to the failure to differentiate between species (35).  If 215 
reference or research facilities are accessible, molecular based techniques are available which can 216 
differentiate the two species based on the size of amplicons generated following PCR targeting the 5’ 217 
region of the mba gene or with real-time based molecular probes (42-44).  Additionally, multiplex 218 
molecular assays are also commercially available and may play an important role in the species-level 219 
identification of Ureaplasma spp., alongside more traditional STI pathogens. As discussed below, the 220 
presence of    221 
 222 
Risk factor 2: The sexual history of the patient  223 
It would be very simplistic to assume that the species of Ureaplasma was the sole differential which 224 
accounts for NGU among men and the inconsistency in reporting in previous cases.  A fascinating 225 
insight most likely relating to the immune response of the host and the transition from pathogen to 226 
commensal has instead been indicated.  For many STIs the risk of symptomatic disease is proportional 227 
to the number of sexual partners (36). In contrary to this, the relationship between Ureaplasma spp. 228 
and number of sexual partners is inversely correlated (17, 45).  Some of the pioneering work in this 229 
area was identified by Wetmore et al., who examined 329 patients with NGU, defined as > 5 PMNs 230 
per high-powered field and/or visible discharge (17).  In this study, two control groups were also 231 
assessed, consisting of 191 attendees to a Sexually Transmitted Disease (STD) clinic and 193 patients 232 
who were attending the emergency department who did not have NGU.  Upon initial analysis, U. 233 
urealyticum was only marginally associated with NGU compared with the STD control group (adjusted 234 
odds ratio 1.6) or the emergency department group (adjusted odds ratio 1.7), but when the analysis 235 
considered the number of sexual partners the adjusted odds ratio rose to 2.9 for the STD group and 236 
3.2 for the emergency department group when focusing on less than ten vaginal partners.  This 237 
association was even greater when the number of vaginal partners was restricted to less than five with 238 
an adjusted odds ratio increasing to 6.2 and 5.2, respectively.  When the same analysis was performed 239 
on patients positive for U. parvum, there was no association among any group, adding further 240 
weighting to the argument to differentiate the species of Ureaplasma.  A similar finding was noted by 241 
Frolund et al., who examined a Danish cohort of 211 NGU patients and 73 asymptomatic controls (45).  242 
Again, a similar finding was observed with the increase in number of sexual partners being associated 243 
with a reduced likelihood of disease.  244 
These studies suggest that Ureaplasma spp. infections resulting in NGU are associated with patients 245 
with fewer sexual contacts.  At first, this may seem counter-intuitive, considering other sexually 246 
transmitted infections are positively associated with the number of sexual contacts and therefore 247 
represents a significant risk factor.  The scenario with Ureaplasma spp. suggests a significant role for 248 
the adaptive immune system in the presentation of disease.  Early work by Brown et al., examined the 249 
serological response to Ureaplasma spp. among NGU patients in acute and convalescent serum (46).  250 
They noted that a change in antibody titre was identified in 68% of patients in which greater than 80% 251 
saw a change in IgM titre suggesting an active infection. When examining titres of IgG and IgA, the 252 
immunoglobulins responsible for protective immunity, only 10% of patients had an increase in titre.  253 
When the data was stratified by prior NGU or not there was no significant difference in IgG levels in 254 
either acute or convalescent serum, whereas prior NGU accounted for a greater IgA response.  These 255 
data suggest that some patients gained protective immunity following previous NGU, whereas others 256 
did not.  This ability to develop protective immunity may account for why some individuals do not 257 
develop NGU on future re-exposure, whereas others may. 258 
 259 
Risk factor 3: The bacterial load of Ureaplasma spp. within the male urethra 260 
The third significant risk factor linking U. urealyticum, and in some cases U. parvum, to development 261 
of NGU is bacterial load within the urethra.  As mentioned previously, in vitro stimulation on monocytic 262 
cell lines with U. urealyticum resulted in a dose-dependent response between the U. urealyticum titre 263 
added and mRNA and cytokine production for the pro-inflammatory cytokines IL-6 and TNF-α (33).  264 
This in vitro evidence is supported by clinical findings from a number of studies (45, 47, 48).  Frolund 265 
et al., reported that in the presence of U. urealyticum at concentrations of > 1.3 x 103 genome 266 
equivalents/ml of urine, corresponding to approximately 1 x 103 bacteria/ml, there was a significant 267 
association with development of NGU (45).  This figure was similar to earlier papers which looked at 268 
cut off points for bacterial load for both U. urealyticum and U. parvum (47, 48).  It is important to note 269 
that the study by Deguchi et al., reported that 83% of subjects which were positive for U. parvum had 270 
less than 5 x 103 bacteria/ml urine of which 80 % had less than 12.5 leukocytes/ml (48).  This gives 271 
further weighting to the idea that U. parvum are less pro-inflammatory, but in situations in which high 272 
titres of U. parvum are present they have the capacity to generate an inflammatory response. An 273 
observation by Frolund et al., ties in Risk Factor 2 (sexual history of the patient) with Risk Factor 3 274 
(bacterial load) (48).  Analysis of their cohort identified that as the number of vaginal sexual partners 275 
increased, the load of Ureaplasma isolated decreased with a predicted drop by 2.2 % with each 276 
additional sexual partner.  It is conceivable that the host immune response which develops due to 277 
multiple exposures to Ureaplasma spp. may have a direct impact on keeping the titre of Ureaplasma 278 
spp. low and therefore under the threshold to mount a significant proinflammatory response as would 279 
result in a PMN response, but these findings needs to be expanded by future studies. 280 
The data from studies presented here suggest that a simple qualitative result would not be enough to 281 
predict a causal relationship between the presence of Ureaplasma spp. and NGU, a factor which has 282 
been overlooked by previous studies.  From these data it may be possible to develop an objectively 283 
determined titre of Ureaplasma spp. which clinical laboratories could use to differentiate between 284 
causality or association. 285 
Impact of Ureaplasma spp. on male fertility 286 
The link between sexually transmitted pathogens and a negative impact on fertility in females is well 287 
established. In males, however, such a link is less defined, yet it has been controversially suggested by 288 
some that Ureaplasma spp. may be associated with male infertility (Table 2). The chronic and often 289 
asymptomatic carriage of Ureaplasma spp. may therefore have important implications on the 290 
development and progression of infertility among men.  In this section we will discuss the studies 291 
which have contributed to this argument and examine the clinical and mechanistic studies which 292 
contribute towards the argument for a causal role of Ureaplasma spp. in impaired male fertility.  293 
Clinical studies associating Ureaplasma spp. with infertility 294 
As discussed, Ureaplasma spp. can be found in the male urethra among seemingly healthy individuals, 295 
but have also been isolated from expressed prostatic secretions, urine following prostatic massage 296 
and prostate tissue (49-53).  This colonisation therefore permits a source to contaminate semen 297 
during ejaculation and serve as means to impact on male fertility. 298 
Many studies have examined the clinical association between the presence of Ureaplasma spp. in men 299 
who are infertile compared with a control group of men without signs of infertility (53-57). In one 300 
relatively small study of 100 infertile and 100 control individuals the authors identified 12% of infertile 301 
men as Ureaplasma spp. positive by PCR compared with only 3% of fertile men (53). The individuals 302 
which were Ureaplasma spp. positive and infertile had significantly lower volumes of seminal fluid, 303 
lower concentrations of sperm cells, and higher levels of sperm cells with abnormal morphology when 304 
compared to the Ureaplasma spp.-negative infertile patients.  Of significance, was the finding that U. 305 
urealyticum in semen of infertile men was found to be higher (9%) than in healthy controls (1%) 306 
whereas the presence of U. parvum was 3% in the infertile group and 2% in healthy men suggesting 307 
U. parvum may not have a causal role in infertility in this patient group. In a similar fate to previous 308 
NGU studies, many have neglected to differentiate between species and in one instance examined in 309 
excess of 19,000 samples which although identified a significant negative impact of Ureaplasma spp. 310 
on semen quality, further power may have been afforded if species-level discrimination had been 311 
conducted (57, 58).  To further investigate the species-specific association on infertility, a meta-312 
analysis was conducted which examined 14 studies comprising 611 cases and 506 controls (56).  These 313 
studies suggested an association between U. urealyticum and a negative impact on fertility, whereas 314 
there was little evidence for a role of U. parvum, which draws a parallel to that of NGU patients, as 315 
discussed previously.  316 
 317 
Proposed mechanisms of Ureaplasma spp. associated infertility 318 
It is important to discuss the proposed mechanisms behind these observations of Ureaplasma spp. 319 
contributing to infertility amongst men (Figure 2). Sexually transmitted pathogens are known to affect 320 
sperm quality by reducing motility, negatively effecting sperm morphology and inducing apoptosis (5).   321 
Several mechanisms have been proposed to account for infertility in men because of Ureaplasma spp. 322 
colonisation.  These include direct binding of Ureaplasma spp. to spermatozoa, which may impede 323 
swimming motility (59-62); to production of toxic metabolites, which can damage spermatozoa 324 
membranes and result in DNA fragmentation (54, 63); as well as the host generation of cross-reactive 325 
antibodies between Ureaplasma spp. and sperm surface proteins (64-66). 326 
The work by Potts et al. identified 17 out of 50 chronic prostatitis patients to be positive for 327 
Ureaplasma spp., in which the levels of reactive oxygen species (ROS) were significantly higher among 328 
the Ureaplasma-positive infertile patients compared with the Ureaplasma-negative infertile patients 329 
and control group (63).  ROS have the potential to induce lipid peroxidation, therefore compromising 330 
the integrity of sperm membranes and leading to impaired fertilization capabilities.  Of interest was 331 
the finding that only one out of seventeen of the positive samples in which ROS were elevated showed 332 
signs of leukocytospermia suggesting that in some cases traditional signs of prostatitis, such as 333 
leukocytospermia, may not be indicative of Ureaplasma spp. infection.  The potential for Ureaplasma 334 
spp. to contribute to lipid peroxidization through generation of ROS, as well as malondialdehyde 335 
formation was further developed and stratified by either U. urealyticum or U. parvum (54). ROS levels, 336 
malondialdehyde, and DNA fragmentation, were all significantly higher in U. urealyticum positive 337 
samples compared with U. parvum. The high levels of ROS could therefore result in DNA fragmentation 338 
and subsequent apoptosis (67). 339 
Some studies have suggested the presence of Ureaplasma spp. in seminal fluid has no real impact on 340 
semen quality (68, 69).   One possibility is that the mechanism associated with infertility is one which 341 
cannot be identified by classic markers of infertility, but may impact on the interaction between the 342 
sperm and egg.  P34H is a key membrane bound protein, which is essential for sperm-zona pellucida 343 
interactions. P34H is incorporated into membranes covering the acrosomal cap as it transits across 344 
the epididymis and therefore can serve as a marker for epididymal function (67).   In the Ureaplasma 345 
spp. positive group, levels of P34H were significantly lower than that of control groups, as determined 346 
by western blot and immunofluorescence imaging, which identified 38% of sperm with P34H in the 347 
Ureaplasma spp. positive group compared with 73% in the control group.  These data suggest a 348 
potential impact of chronic asymptomatic infection of the epididymis. The acrosomal cap also contains 349 
the enzyme hyaluronidase (HYD) which is essential for the sperm to penetrate the egg. In the 350 
Ureaplasma spp. positive group, levels of HYD activity were significantly different between the 351 
infertile Ureaplasma spp. positive group as well as the infertile Ureaplasma spp. negative group and 352 
fertile controls (67).  By reducing the activity of HYD the likelihood of successful sperm penetration 353 
into the egg is therefore reduced. 354 
An alternative mechanism to Ureaplasma-related infertility is the development of cross-reactive 355 
antibodies to human sperm membrane proteins following exposure to Ureaplasma spp. (64-66). Shi 356 
demonstrated that antibodies raised against the UreG protein of Ureaplasma spp. were able to cross-357 
react with human nuclear autoantigenic sperm protein (NASP). A higher titre of anti-UreG antibody 358 
was found in the sera of infertile men compared with fertile controls.  In an in vitro fertility assay, 359 
sperm which had been pre-treated with anti-UreG antibodies had significantly lower binding and 360 
fusion to eggs compared with non-treated controls. 361 
The evidence presented here suggests that the impact of Ureaplasma spp. on male infertility is similar 362 
to that described for NGU, although unlike in the context of NGU the effect of bacterial titre has yet 363 
to be investigated.  The lack of species differentiation has hindered studies, but association as well as 364 
mechanistic studies are pointing towards a potential for U. urealyticum as the primary Ureaplasma 365 
spp. associated with infertility in men.  Furthermore, some of the traditional markers for infertility 366 
may not indicate a causal role for Ureaplasma spp. in male infertility. 367 
Treatment of genital tract infections in men caused by Ureaplasma spp. 368 
A position statement from the European STI Guidelines Editorial Board states that routine testing of 369 
asymptomatic or symptomatic men for the presence of Ureaplasma spp. is not recommended, 370 
however, one of the key messages the authors made states that Ureaplasma urealyticum in high 371 
bacterial loads can cause a small proportion of male NGU (3-11% of NGU cases) (4). The authors also 372 
noted that NGU caused by U. urealyticum was more likely to develop in younger men and men with 373 
fewer lifetime sexual partners. They highlight that there is a paucity of well-designed large controlled 374 
studies which investigate the role of Ureaplasma spp. with STI syndromes and NGU.  375 
 376 
In the light of mounting evidence of a causal role for Ureaplasma spp. in the development of NGU and 377 
male infertility, the question remains whether we should treat individuals who are Ureaplasma spp. 378 
positive with symptoms. Currently, a Position Statement from the European STI Guidelines Editorial 379 
Board does not recommend routine testing or treatment of either asymptomatic or symptomatic men 380 
for any Ureaplasma spp., however this Position Statement also suggests that U. urealyticum is causal 381 
in up to 11% of NGU cases which contradicts this recommendation (4).  The evidence presented in this 382 
review suggests that in a subset of men with symptoms of NGU and the absence of other aetiological 383 
factors, a risk-based approach could be used to guide treatment of these patients. For example, 384 
symptomatic NGU patients, with the absence of other sexually transmitted infections, younger age, 385 
low number of partners and high titres of U. urealyticum may benefit from treatment. Currently it is 386 
clinically difficult to implement a risk-based approach in countries such as the UK as sexual healthcare 387 
settings do not widely test for Ureaplasma spp. and when done it almost never involves differentiation 388 
of U. urealyticum and U. parvum or determination of bacterial load.  389 
 390 
Currently guidelines set out by the British Association for Sexual Health and HIV (BASHH) suggest 391 
treatment of a first episode of NGU with a 7 day course of doxycycline 100mg twice daily or if 392 
contraindicated, azithromycin 1g STAT followed by 500mg once daily for two days, or ofloxacin 200mg 393 
twice daily, or 400mg once daily, for 7 days (70).  With recurrent episodes of NGU, where re-infection 394 
has been excluded, the recommended first line regimen is azithromycin 1g STAT then 500mg once 395 
daily for the next two days, plus metronidazole 400mg twice daily for five days.  If symptoms still 396 
persist, treatment with moxifloxacin 400mg once daily for 10-14 days, plus metronidazole 400mg 397 
twice daily for five days is the recommended regimen. It is considered reasonable to provide 398 
epidemiological treatment to the partners of men with NGU using the same antimicrobial regimen 399 
that resulted in cure in the index case. In practice, if Ureaplasma spp. were present and responsible 400 
for symptoms of NGU, the first-line treatment recommended (a short course of doxycycline 100mg bd 401 
for 7 days) would be adequate to treat it in the UK at the moment in light of low levels of tet(M) 402 
mediated doxycycline resistance among these organisms (71). Any decision to treat would need to be 403 
carefully weighed up with the risk of inappropriate prescribing.  Antibiotic resistance, in particular 404 
azithromycin resistance, among recognised GUM pathogens such as M. genitalium and N. 405 
gonorrhoeae is of growing concern (72, 73). 406 
Summary 407 
The role in which Ureaplasma spp. play in the development of genitourinary medicine-related 408 
infections is still a controversial area for many, but there is mounting evidence that these bacteria, 409 
especially U. urealyticum, have a causative role in infection under very specific conditions.  410 
Ureaplasma spp. are by no means a leading cause of NGU, but this is not to say that they do not 411 
contribute to cases which are currently classified as idiopathic; as such these patients are no less 412 
deserving of attention or correct management. Furthermore, the role of Ureaplasma spp. in the 413 
development of infertility among men is beginning to be recognised, but further work exploring the 414 
mechanism, as well as appropriate criteria for identifying patients with Ureaplasma spp.-induced 415 
infertility is required. 416 
Ureaplasma spp. have a proven proinflammatory capacity in cell lines, animal and human models of 417 
disease, but the species of Ureaplasma spp., the sexual history of the patient and titre of bacteria 418 
present all appear to be key risk factors for the development of disease. A large prospective case-419 
controlled study considering the species and load of Ureaplasma, presence of other microorganisms, 420 
number of PMNs as a marker of inflammation and number of sexual partners will be crucial to confirm 421 
or refute the role of Ureaplasma spp. in the development of NGU in men. If a clear link is identified, 422 
then current qualitative diagnostic methods may not be appropriate for determining a causal role for 423 
Ureaplasma spp. in cases of NGU.  In the meantime, in light of the evidence presented in this review, 424 
we recommend that among cases of symptomatic NGU, in which classic aetiological agents have been 425 
ruled out, a risk-based approach taking into account patients with a younger age, low number of 426 
partners and high-titres of U. urealyticum should be considered for treatment.   427 
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Figure Legends 625 
 626 
Figure 1. Proposed natural history of U. urealyticum urethral infection in men following initial 627 
exposure. A hypothetical scenario in an immunologically naïve male when exposed to U. urealyticum 628 
for the first time. The lack of prior exposure to U. urealyticum results in an increased bacterial titre 629 
and subsequent polymorphonuclear neutrophil influx (signs of infection) with accompanying 630 
symptoms. Depending on the adaptive immunological response to U. urealyticum, the infection may 631 
clear without intervention or result in persistent urethral colonisation. With an increase in number of 632 
sexual contacts the presence of an adaptive immune response is able to keep the titre of any newly 633 
acquired U. urealyticum below the threshold which results in inflammation.  In the absence of an 634 
adaptive immune response signs and symptoms may be present again.  Persistent urethral 635 
colonisation may result in a commensal-like association with the host, accounting for the high 636 
prevalence among healthy individuals, or alternatively may result in the factors which are associated 637 
with the development of infertility.  638 
 639 
 640 
Figure 2. Mechanisms associated with Ureaplasma spp.-induced infertility in men. A number of 641 
mechanisms have been proposed to account for the clinical observational studies showing decreased 642 
fertility among men who experience urethral colonisation with Ureaplasma spp. These include 1. 643 
Cross-reactivity of host generated antibodies against the UreG protein of Ureaplasma spp. to the 644 
autoantigenic sperm protein. 2. Generation of toxic compounds such as reactive oxygen species (ROS) 645 
which contributes to lipid peroxidation, DNA fragmentation and subsequent apoptosis. 3. Direct 646 
binding to spermatozoa which may result in reduced motility. 4. Reduced incorporation of P34H and 647 
hyaluronidase activity in the acrosomal cap, which may reduce the capacity of spermatozoa to 648 
penetrate the egg. 649 
 650 
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45 Sweden Male patients 




• 187 men with 
acute NGU 
• 24 men with 
chronic NGU 




Yes • Number of lifetime sexual partners 
was negatively associated with U. 
urealyticum load. 
• Urine containing U. urealyticum 
with > 1.3 x 103 genome 
equivalents/ml were associated 
with NGU. 
Cox et al. 
(2016) 
41  UK Male patients 
attending a GUM 
clinic 
Urine • 75 men with 
NCNGU 





Yes • Significantly higher prevalence of 
U. parvum in the NCNGU group. 
• No association between U. 




19 UK Males attending an 
urban Sexual Health 
Clinic 




Yes • Only four patients were positive 




48 Japan Retrospective study 











qPCR Yes • U. parvum load of > 5 x 103 
cells/ml were significantly 
associated with > 12.5 
leucocytes/µl of urine. 
• 83% of subjects had < 5 x 103 
cells/ml suggesting a low bacterial 
load and lack of signs of 
inflammation. 





Meta-analysis N/A • 1507 men with 
NGU 
• 1223 men 
without NGU 
N/A Yes • No significant difference between 
undifferentiated Ureaplasma spp. 
positive rate between NGU and 
control group. 
• When species was differentiated 
U. urealyticum was significantly 
associated with the NGU group 
whereas U. parvum was 





47 Japan Retrospective study 











Yes • Bacterial load of U. urealyticum 
was positively correlated with NGU 




17 USA Men attending STD 
clinic 
Urine • 329 men with 
NGU 
• Control Group 






• Control Group 





Culture Yes  • U. urealyticum was associated with 
NGU. 
• Association was significantly 
stronger when analysing men with 
<10 vaginal partners. 
• Association was further 
strengthened when analysing men 
with <5 vaginal partners. 





38 Australia Men attending a 




• 237 men with 
NGU 
• 268 controls 
PCR Yes • U. urealyticum was significantly 
associated with NGU in the 





21 USA Archived samples 
from heterosexual 
males attending STD 
clinic 
Urine • 119 men with  
NGU 
• 117 controls 
PCR Yes • U. urealyticum was strongly 
associated with NGU. 
• This association was strongest in 
men <28 years of age. 
• U. parvum not associated with 
NGU. 








Urine • 98 men with 
NGU 







• Neither Ureaplasma nor M. 





39 Australia Men attending a 




• 329 men with 
NGU 
• 307 controls 
PCR Yes • Neither U. urealyticum nor U. 





36 Sweden Men attending a 
sexual health clinic 
Urethral 
swab 
• 125 men with 
NGU 
• 205 without 
NGU 
PCR Yes • No difference between NGU and 
non-NGU group if Ureaplasmas 
were not differentiated to the 
species level. 
• When differentiated, significantly 
more U. urealyticum were 
associated with males with NGU 




16 UK Heterosexual men 





• 114 men with 
NGU 
• 64 without 
NGU 
Culture No • Ureaplasmas were not associated 
with acute NGU. 
• Ureaplasmas were associated with 
NGU during follow-up. 
• Ureaplasmas were associated with 
chronic NGU. 
Table 1.  Published studies examining the relationship between Ureaplasma spp. and non-gonococcal urethritis.  PCR = Polymerase Chain Reaction. NCNGU = Non-696 
chlamydial non-gonococcal urethritis. N/A = not applicable. 697 
 698 
 699 





Patient group Sample 
type 








57 China Men attending 
a reproductive 
centre 
Semen • 19,098 
infertile men 
• 3,368 fertile 
men  
Culture No • Ureaplasma spp. were significantly 
associated with infertility. 
• Ureaplasma spp. were significantly 
associated with reduced motility and 







Meta-analysis N/A • 611 infertile 
men 
• 506 fertile 
men 
N/A Yes • U. urealyticum was significantly 
associated with infertility. 




54 China Men attending 
an infertility 
clinic 
Semen • 223 infertile 
men 
• 146 fertile 
men 
Culture Yes • U. urealyticum was significantly 
associated with infertility compared 
with U. parvum.  
• Semen positive for U. urealyticum 
showed decreased concentration of 





55 Jordan Men attending 





• 93 infertile 
men 
• 70 fertile men 
PCR Yes • Ureaplasmas were found more 
frequently among samples from 





53 Iran Men attending 
an infertility 
centre 
Semen • 100 infertile 
men 
• 100 fertile 
controls 
PCR Yes • Ureaplasmas were detected 
significantly more often in semen 
from infertile men compared with 
controls. 
• U. urealyticum was detected in 9% 
of infertile men vs 1% of control 
men. 
• U. parvum was detected in 3% of 
infertile men vs 2% of control men. 
 701 
Table 2.  Published studies examining the relationship between Ureaplasma spp. and male infertility. PCR = Polymerase Chain Reaction. N/A = not applicable. 702 
